Radiologic-pathologic correlation in breast cancer: do MRI biomarkers correlate with pathologic features and molecular subtypes?

European Radiology Experimental

Table 6 Correlation between triple-negative tumours and magnetic resonance imaging features

		Triple negative	χ2 analysis p-value	Univariate analysis		Multivariate analysis
				OR (CI 95%)^a	p-value	OR (CI 95%)^a	p-value
No. of patients		37
Tumour size	Median (mm) Range (mm)	23 9–90
≥ 2 cm		24/37	0.207	1.645 (0.756–3.577)	0.209
T2 intensity	Hypointensity Isointensity Hyperintensity	12/37 12/37 13/37	0.173	0.480 (0.218–1.056) 1.690 (0.737–3.875) 1.401 (0.630–3.116)	0.068 0.215 0.409
Mass enhancement		30/37	0.967	1.020 (0.392–2.655)	0.967
Shape (Mass)	Round Oval Irregular	26/30 0/30 4/30	0.001	7.150 (2.295–22.28) Out of scale 0.205 (0.066–0.640)	0.001 0.006	5.319 (1.425–19.85)	0.013
Rim enhancement		22/30	< 0.001	9.408 (3.613–24.50)	< 0.001	9.155 (2.537–33.04)	0.001
Intralesional necrosis		27/37	< 0.001	5.559 (2.416–12.79)	< 0.001	0.846 (0.214–3.340)	0.811
Perilesional oedema		30/37	< 0.001	5.844 (2.352–14.52)	< 0.001	3.852 (1.092–13.59)	0.036
Abnormal lymph nodes		18/37	0.106	1.868 (0.871–4.003)	0.108
Intensity-to-time curve	Type I Type II Type III	3/37 10/37 24/37	0.969	0.931 (0.238–3.644) 1.111 (0.475–2.601 0.936 (0.426–2.059)	0.919 0.808 0.870
ADC value	Very low Low Intermediate	24/32 7/32 1/32	0.106	2.264 (0.921–5.565) 0.388 (0.152–0.986) 2.968 (0.180–48.88)	0.075 0.047 0.447	4.762 (0.018–1277)	0.584
Extent of disease	Unifocal Multifocal Multicentric	15/37 10/37 12/37	0.530	0.765 (0.358–1.638) 0.872 (0.377–2.017) 1.600 (0.701–3.654)	0.491 0.749 0.265